---
title: "300636.SZ (300636.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300636.SZ/news.md"
symbol: "300636.SZ"
name: "300636.SZ"
parent: "https://longbridge.com/en/quote/300636.SZ.md"
datetime: "2026-05-21T00:58:45.839Z"
locales:
  - [en](https://longbridge.com/en/quote/300636.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300636.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300636.SZ/news.md)
---

# 300636.SZ (300636.SZ) — Related News

### [SYNERGY's empagliflozin tablets have obtained a drug registration certificate](https://longbridge.com/en/news/286760258.md)
*2026-05-18T11:10:03.000Z*
> SYNERGY recently obtained the "Drug Registration Certificate" for Empagliflozin Tablets approved by the National Medical

### [SYNERGY: A foreign exchange risk monitoring mechanism has been established to effectively reduce the impact of exchange rate fluctuations on the company's performance](https://longbridge.com/en/news/286646046.md)
*2026-05-16T13:05:22.000Z*
> SYNERGY stated at the earnings briefing that it has established an exchange rate risk monitoring mechanism to reduce the

### [SYNERGY: The active pharmaceutical ingredient Canagliflozin has received the registration approval letter from the U.S. FDA](https://longbridge.com/en/news/286353527.md)
*2026-05-14T03:55:03.000Z*
> SYNERGY recently received the registration approval letter for Canagliflozin active pharmaceutical ingredient issued by 

### [Another major pharmaceutical OEM has encountered issues, this time it is Xiu Zheng Pharmaceutical](https://longbridge.com/en/news/279264412.md)
*2026-03-16T12:12:19.000Z*
> Xiu Zheng Pharmaceutical has recently come under scrutiny due to issues with its private label products. Media reports h

### [SYNERGY: Fumaric Acid Vorinostat raw materials approved by CDE](https://longbridge.com/en/news/276871946.md)
*2026-02-25T10:38:04.000Z*
> SYNERGY announced that its submitted active pharmaceutical ingredient "Fumaric Acid Vinorelbine" has been approved by th

### [SYNERGY: The raw material drug tosilic acid edoxaban has passed CDE approval](https://longbridge.com/en/news/274790539.md)
*2026-02-04T09:52:13.000Z*
> SYNERGY announced that the "Tobiasulfate Edoxaban" active pharmaceutical ingredient submitted by the company has passed 

### [Zhitong A-share lock-up release overview | January 20](https://longbridge.com/en/news/273012230.md)
*2026-01-20T01:01:02.000Z*
> On January 20th, a total of 2 listed companies had their restricted shares unlocked, with a total market value of approx

### [SYNERGY passed the on-site inspection by the U.S. FDA](https://longbridge.com/en/news/263970567.md)
*2025-11-03T08:53:12.000Z*
> SYNERGY underwent a cGMP on-site inspection by the U.S. FDA from August 4 to August 7, 2025, covering six major systems: